SAN FRANCISCO, California. (November 17, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting at the 2014 Jefferies Global Healthcare Conference in London on Thursday, November 20, 2014 at 5:00 PM GMT.
The presentation will be webcast live over the Internet and can be accessed through the Investors/Events section of KindredBio’s website at www.kindredbio.com. To access the live webcast, please log on to KindredBio’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for 30 days following the event.
About Kindred Biosciences
Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company’s lead product candidates are AtoKin™ (fexofenadine) for the treatment of atopic dermatitis in dogs and SentiKin™ (flupirtine) for the treatment of post-operative pain in dogs and cats.